Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MG149
- Development stage
- Unknown
- Lead developer
- University of Georgia
- Modality
- Small Molecules
- Administration
- Intraperitoneal
01
Overview
MG149 is a selective, cell-permeable small molecule inhibitor of the MYST family of histone acetyltransferases (HATs), primarily targeting Tip60 (KAT5) and MOF (KAT8). It acts as an anacardic acid analog, competitively inhibiting Tip60 with respect to acetyl-CoA, and uncompetitively inhibiting KAT8. MG149 is widely utilized as a preclinical research tool to study histone acetylation, chromatin regulation, and the role of MYST family HATs in various pathological processes, including inflammatory lung diseases, acute myeloid leukemia, and bladder cancer.
- Other names
- 2-(4-heptylphenethyl)-6-hydroxybenzoic acid2-[2-(4-heptylphenyl)ethyl]-6-hydroxybenzoic acidTip60 HAT inhibitorTip-60 HAT inhibitorTip 60 HAT inhibitor
02
Targets
KAT5 (Lysine acetyltransferase 5)KAT6A (Lysine acetyltransferase 6A)KAT8 (KAT8 / MOF)
Beyond the preview
Go deeper on MG149.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MG149.